Immune Persistence and Safety Pediatric Survey (Aged 5-11 Years) related to the SARS-CoV-2 Vaccination (Primary series and Booster Vaccination) in Japa

Not Applicable

• Conditions: COVID-19

• Registration Number: JPRN-UMIN000047368
• Lead Sponsor: Juntendo University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-04-02
• Last Update Posted: 2 September 2024
• Study Completion: 2025-03-31

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 411

Inclusion Criteria

Not provided

Exclusion Criteria

Those who are inappropriate as the subject of the survey determined by the principal investi gator.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety up to 4 weeks after the last vaccination of SAR S-CoV-2 vaccine

Secondary Outcome Measures

Name	Time	Method
1) Breakthrough infection rate up to 6 months after the final vaccination of SARS-CoV-2 vaccine. 2) Serious adverse events up to 6 months after the final vaccination of SARS-CoV-2 vaccine (regardless of causality). 3) Changes in COVID-19 antibody titer up to 6 months after the final vaccination of SARS-CoV-2 vaccine (some of the survey subjects).